Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2024; 30(42): 4591-4596
Published online Nov 14, 2024. doi: 10.3748/wjg.v30.i42.4591
Helicobacter pylori, esophageal precancerous lesions, and proton pump inhibitor overuse
Feng Zhang, Hang Zhang, Yan-Miao Liu, Fu-Shan Tang
Feng Zhang, Hang Zhang, Fu-Shan Tang, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Feng Zhang, Hang Zhang, Fu-Shan Tang, Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Yan-Miao Liu, The First Clinical Institute, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Fu-Shan Tang, Key Laboratory of Clinical Pharmacy in Zunyi City, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Author contributions: Zhang F drafted and revised the manuscript; Zhang H and Liu YM provided discussion and literature support; Tang FS contributed to idea generation, revised the manuscript, and provided supervision; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com
Received: August 21, 2024
Revised: September 20, 2024
Accepted: October 8, 2024
Published online: November 14, 2024
Processing time: 71 Days and 4.3 Hours
Core Tip

Core Tip: This article reviews a recent cohort study suggesting that Helicobacter pylori (H. pylori) infection may protect against esophageal cancer. We discuss the controversial link between H. pylori and esophageal precancerous lesions and address risks associated with proton pump inhibitor (PPI) overuse. The implications for cancer treatment and the need for further research on PPI safety and efficacy in cancer patients are highlighted.